TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28035498

Group type: EXPERIMENTAL
Intervention: Conventional CXL (3 mW/cm2 for 30 min)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Accelerated CXL (9 mW/cm2 for 10 min)
Number of subjects: 15
Study: 26771913

Group type: COMPARATOR
Intervention: Methylphenidate (MPH)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Physical Activity (PA)
Number of subjects: 112
Study: 24795515

Group type: EXPERIMENTAL
Intervention: Aloe vera mouthwash
Number of subjects: 300

Group type: COMPARATOR
Intervention: 0.2% chlorhexidine gluconate mouthwash
Number of subjects: 300

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 300
Study: 24349414

Group type: EXPERIMENTAL
Intervention: Tinnitus pitch matching using the likeness rating method with pure tones from 0.25 to 16 kHz.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous-pitch method for tinnitus pitch matching (0.5 to 20 kHz in 1-Hz steps).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Assessment of loudness ratings by simulated malingerers.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Retest data for pitch matching responses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychoacoustic loudness matches.
Number of subjects: 0
Study: 20510972

Group type: EXPERIMENTAL
Intervention: Brain Injury Coping Skills Group (12-session, manualized cognitive-behavioral treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brain Injury Coping Skills Group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 18492416

Group type: EXPERIMENTAL
Intervention: docetaxel-epirubicin
Number of subjects: 41

Group type: COMPARATOR
Intervention: 5-fluorouracil-epirubicin-cyclophosphamide
Number of subjects: 41
Study: 16603132

Group type: EXPERIMENTAL
Intervention: Pergolide (D1/D2 agonist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bromocriptine (D2 agonist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12923400

Group type: EXPERIMENTAL
Intervention: Trimethaphan 2‐4 mg/min (autonomic blockade)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LF(SBP)
Number of subjects: 0
Study: 11013282

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 5613
Study: 9201796

Group type: EXPERIMENTAL
Intervention: Abecarnil 5.0 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Abecarnil 2.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lorazepam 2.0 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1443511

Group type: EXPERIMENTAL
Intervention: Ketanserin (0.3 mg.kg‐1 bolus followed by 0.06 mg.kg‐1.h‐1 infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (without ketanserin)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 20
Study: 3541499

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 26
Study: 29993224

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment with nasal irrigation of normal saline (4 times daily) and nasal corticosteroids (one puff in each nostril daily)
Number of subjects: 30
Study: 26329584

Group type: EXPERIMENTAL
Intervention: Resolute integrity zotarolimus-eluting stents (Medtronic)
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Promus element everolimus-eluting stents (Boston Scientific)
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Bifurcated lesions
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Non-bifurcated lesions
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Two-stent approaches
Number of subjects: 1811

Group type: COMPARATOR
Intervention: Single-stent approaches
Number of subjects: 1811
Study: 25355484

Group type: EXPERIMENTAL
Intervention: Fish oil (FO) supplementation (2 × 1 g/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (soya bean oil, 2 × 1 g/d)
Number of subjects: 26
Study: 21915043

Group type: EXPERIMENTAL
Intervention: 11-week computer intervention with nine online self-study health teaching units
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 21311484

Group type: EXPERIMENTAL
Intervention: Cytoflavin treatment (20 ml in 400 ml of 0.9% NaCl solution twice a day intravenously for days 1-10; 850 mg twice a day for days 11-35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (basic therapy aimed at improving systemic hemodynamics, rheological blood properties, and prevention of stroke complications)
Number of subjects: 70
Study: 17999226

Group type: EXPERIMENTAL
Intervention: Self referent condition
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Spider fearful participants
Number of subjects: 211

Group type: COMPARATOR
Intervention: Other groups (blood fearful and nonfearful)
Number of subjects: 211
Study: 16254521

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) 4000
Number of subjects: 96

Group type: COMPARATOR
Intervention: Lactulose
Number of subjects: 96
Study: 11527057

Group type: EXPERIMENTAL
Intervention: Brisk walking (Sed/Walk)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Brisk walking (Walk/Walk)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Ceasing brisk walking (Walk/Sed)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Sedentary lifestyle (Sed/Sed)
Number of subjects: 68
Study: 9032647

Group type: COMPARATOR
Intervention: Polymorphic markers in the GDE gene (‐10G/A, 2001 + 8C/T, 3199C/T)
Number of subjects: 0
Study: 8391569

Group type: EXPERIMENTAL
Intervention: Psyllium fiber (6 gm/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control cereal (without psyllium fiber)
Number of subjects: 20
Study: 3554800

Group type: EXPERIMENTAL
Intervention: Ruscus extract, trimethyl hesperidine chalcone and ascorbic acid (Phlebodril)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30876827

Group type: EXPERIMENTAL
Intervention: Higher-fat diet (fat 40%, carbohydrate 46%, protein 14%)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Higher-fat diet
Number of subjects: 3
Study: 29957664

Group type: EXPERIMENTAL
Intervention: Low-Level Light Therapy (LLLT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham light treatment
Number of subjects: 100
Study: 27465740

Group type: EXPERIMENTAL
Intervention: Participation in the clinical trial
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Reasons for participation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Understanding of trial elements
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Overall experience
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Impact on clinical outcomes
Number of subjects: 76
Study: 23464642

Group type: EXPERIMENTAL
Intervention: Hydrotherapy (group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Physiotherapy (group 2)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Both physiotherapy and hydrotherapy (group 3, control group)
Number of subjects: 30
Study: 20973770

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with methyl aminolaevulinate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imiquimod cream (5%)
Number of subjects: 0
Study: 18285373

Group type: EXPERIMENTAL
Intervention: Horizontal Position (HP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 15 degrees head-up tilt Position (TP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Three-level Position (3P)
Number of subjects: 18
Study: 16503684

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (0.3 g.kg(‐1) for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 16
Study: 12695317

Group type: EXPERIMENTAL
Intervention: Lamotrigine (100-400 mg daily)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lithium (0.8-1.1 mEq/L)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study: 10847578

Group type: EXPERIMENTAL
Intervention: Expanded Timed Get‐up‐and‐Go (ETGUG) test
Number of subjects: 3

Group type: COMPARATOR
Intervention: Timed Get‐up‐and‐Go (TGUG) test
Number of subjects: 3
Study: 9059472

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 8448257

Group type: EXPERIMENTAL
Intervention: Caffeine and doxapram
Number of subjects: 0

Group type: COMPARATOR
Intervention: Caffeine and placebo
Number of subjects: 0
Study: 2819914

Group type: EXPERIMENTAL
Intervention: brief out‐patient counselling
Number of subjects: 80

Group type: COMPARATOR
Intervention: general practitioner care
Number of subjects: 80
Study: 31930364

Group type: EXPERIMENTAL
Intervention: RimabotulinumtoxinB 2500 U
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: RimabotulinumtoxinB 3500 U
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 30001705

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27567534

Group type: EXPERIMENTAL
Intervention: quantitative cardiotocography (qCTG)
Number of subjects: 720
Study: 23721245

Group type: EXPERIMENTAL
Intervention: CP/fosbretabulin (paclitaxel 200 mg/m² followed by carboplatin AUC 6 on day 1 every 3 weeks, with fosbretabulin 60 mg/m² on days 1, 8, and 15)
Number of subjects: 80

Group type: COMPARATOR
Intervention: CP (paclitaxel 200 mg/m² followed by carboplatin AUC 6 on day 1 every 3 weeks)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CP/fosbretabulin
Number of subjects: 80
Study: 22918559

Group type: EXPERIMENTAL
Intervention: Athletes with asthma (AtAs)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Athletes without asthma (AtNAs)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Non-athlete asthmatics (NAtAs)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-athletes (NAtNAs)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Athletes (both with and without asthma)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-athletes (both with and without asthma)
Number of subjects: 68
Study: 21219810

Group type: EXPERIMENTAL
Intervention: Acetaminophen + B vitamins
Number of subjects: 56

Group type: COMPARATOR
Intervention: Acetaminophen
Number of subjects: 56
Study: 18853551

Group type: EXPERIMENTAL
Intervention: Convex shapes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Congruent shapes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Two index fingers (one per surface)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opponent shapes
Number of subjects: 0
Study: 20878408

Group type: EXPERIMENTAL
Intervention: Theophylline 200 mg IV before the procedure
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15644641

Group type: EXPERIMENTAL
Intervention: 6 mL/kg tidal volume strategy
Number of subjects: 861

Group type: COMPARATOR
Intervention: 12 mL/kg tidal volume strategy
Number of subjects: 861

Group type: EXPERIMENTAL
Intervention: Both tidal volume strategies
Number of subjects: 861
Study: 12111630

Group type: EXPERIMENTAL
Intervention: Chondroitin polysulphate
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 9725631

Group type: EXPERIMENTAL
Intervention: Fatty meal at 08.00 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mixed meal during the day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting during the day
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mixed meal at night
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fasting at night
Number of subjects: 31
Study: 7799895

Group type: EXPERIMENTAL
Intervention: Methimazole treatment (6 month course)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Untreated patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (28 healthy fertile women)
Number of subjects: 20
Study: 3352195

Group type: EXPERIMENTAL
Intervention: Multivitamin preparation without lidocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Multivitamin preparation with 1% lidocaine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Excipient formulation without vitamins (isoosmotic)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Excipient formulation without vitamins (with saline)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Glycine 2.5% (control)
Number of subjects: 10
Study: 29293177

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 40

Group type: COMPARATOR
Intervention: Desflurane/N2O
Number of subjects: 40
Study: 27038098

Group type: EXPERIMENTAL
Intervention: Perampanel (2–12 mg/day, once daily at bedtime)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel (12 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perampanel (not specified dosage)
Number of subjects: 0
Study: 25351220

Group type: EXPERIMENTAL
Intervention: Injection of sodium hyaluronate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Disc repair
Number of subjects: 48
Study: 23566577

Group type: EXPERIMENTAL
Intervention: 7 days of intravenous antibiotics (G1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: 14 days of intravenous antibiotics (G2)
Number of subjects: 53
Study: 20458051

Group type: EXPERIMENTAL
Intervention: Adjuvant classical cyclophosphamide, methotrexate, and fluorouracil (CMF) chemotherapy
Number of subjects: 2257

Group type: COMPARATOR
Intervention: Endocrine therapy alone
Number of subjects: 2257
Study: 17552880

Group type: EXPERIMENTAL
Intervention: Calcium (500 mg/day)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 16644435

Group type: EXPERIMENTAL
Intervention: Doppler echocardiography and NT-proBNP measurements
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Risk stratification model based on restrictive filling pattern, NT-proBNP, and peak early diastolic mitral flow to mitral annular E' velocity
Number of subjects: 73
Study: 12825916

Group type: EXPERIMENTAL
Intervention: Direct hypnosis with standard medical treatment
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Indirect hypnosis with standard medical treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Attention control with standard medical treatment
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard medical treatment alone
Number of subjects: 80
Study: 10661364

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focused expressive psychotherapy (FEP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active group members
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observing group members
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional contagion
Number of subjects: 0
Study: 8675791

Group type: EXPERIMENTAL
Intervention: High-copper content dental amalgam restorations
Number of subjects: 0
Study: 1711250

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA) 50 mg b.i.d.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Subcapsular orchiectomy
Number of subjects: 37
Study: 6355931

Group type: EXPERIMENTAL
Intervention: Lasix
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diurin
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Frusid
Number of subjects: 5

Group type: COMPARATOR
Intervention: Aqueous solution
Number of subjects: 5
Study: 29308939

Group type: EXPERIMENTAL
Intervention: Kinesio Taping (standard treatment plus application of Kinesio Taping on the respiratory muscles)
Number of subjects: 62
Study: 27302183

Group type: EXPERIMENTAL
Intervention: Overweight/obese girls
Number of subjects: 318

Group type: COMPARATOR
Intervention: Normal weight girls
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Overweight/obese boys
Number of subjects: 318

Group type: COMPARATOR
Intervention: Normal weight boys
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Parental educational attainment (master or higher)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Perceived stress
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Duration of T1D
Number of subjects: 318
Study: 24965569

Group type: EXPERIMENTAL
Intervention: Rilotumumab 15 mg/kg plus ECX
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Rilotumumab 7.5 mg/kg plus ECX
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Combined rilotumumab (both doses) plus ECX
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo plus ECX
Number of subjects: 121
Study: 22433755

Group type: EXPERIMENTAL
Intervention: Multifaceted Diabetes and Depression Program
Number of subjects: 387
Study: 20171420

Group type: EXPERIMENTAL
Intervention: NXN-188 (doses of 2 to 800 mg, 0.027-11.2 mg/kg)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: NXN-188
Number of subjects: 203
Study: 18400461

Group type: EXPERIMENTAL
Intervention: HIV/AIDS symptom management manual
Number of subjects: 775

Group type: COMPARATOR
Intervention: Basic nutrition manual
Number of subjects: 775
Study: 16160628

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 62

Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 62
Study: 15132403

Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10, 20, 40, or 80 mg/d)
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin (10 mg ezetimibe + simvastatin at 10 mg/d)
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Ezetimibe coadministered with simvastatin
Number of subjects: 887

Group type: COMPARATOR
Intervention: Simvastatin monotherapy
Number of subjects: 887

Group type: EXPERIMENTAL
Intervention: Ezetimibe/simvastatin and simvastatin monotherapy
Number of subjects: 887
Study: 11298622

Group type: EXPERIMENTAL
Intervention: rhGM‐CSF 2.8 microg per kg body-weight
Number of subjects: 16

Group type: COMPARATOR
Intervention: saline
Number of subjects: 16
Study: 9307639

Group type: EXPERIMENTAL
Intervention: Standardized macular hole surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study: 8370566

Group type: EXPERIMENTAL
Intervention: St. John's wort extract (Hypericum), LI 160
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3723999

Group type: EXPERIMENTAL
Intervention: 1 dose of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 2 doses of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 4 doses of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 8 doses of 0.1 ml human diploid cell vaccine (HDCV)
Number of subjects: 44
Study: 30322724

Group type: EXPERIMENTAL
Intervention: Single-course clindamycin (300 mg twice-daily for 4 days)
Number of subjects: 3105

Group type: EXPERIMENTAL
Intervention: Triple-course clindamycin (300 mg twice-daily for 4 days)
Number of subjects: 3105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3105

Group type: EXPERIMENTAL
Intervention: Triple-course clindamycin (high-risk subtrial)
Number of subjects: 3105

Group type: EXPERIMENTAL
Intervention: Single-course clindamycin (high-risk subtrial)
Number of subjects: 3105

Group type: EXPERIMENTAL
Intervention: Clindamycin (combined low-risk groups)
Number of subjects: 3105
Study: 27385272

Group type: EXPERIMENTAL
Intervention: Sleep education program with self-help treatment
Number of subjects: 243

Group type: COMPARATOR
Intervention: Waiting list group
Number of subjects: 243
Study: 24602074

Group type: EXPERIMENTAL
Intervention: New gelling fibre dressing containing silver (DURAFIBER™ Ag) for a maximum of 8 weeks
Number of subjects: 14
Study: 22391668

Group type: EXPERIMENTAL
Intervention: Bupivacaine (2 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (no infiltration)
Number of subjects: 34
Study: 20702747

Group type: EXPERIMENTAL
Intervention: Grape polyphenols (wine grape solid)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Grape polyphenols (grape seed solids)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 35
Study: 18188762

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (100 microg of purified 3'-aminomethylnicotine conjugated to detoxified Pseudomonas aeruginosa r-exoprotein A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicotine vaccine (fourth dose at day 182)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15879167

Group type: EXPERIMENTAL
Intervention: Oral Contraceptive (OC) users during luteal phase (Lut)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Nonusers of Oral Contraceptives (NOC)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Men
Number of subjects: 23

Group type: COMPARATOR
Intervention: Oral Contraceptive (OC) users during follicular phase (Fol)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Cortisol changes with exercise
Number of subjects: 23
Study: 12519869

Group type: COMPARATOR
Intervention: Energy availability at 30 kcal/kg LBM.d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Energy availability below 30 kcal/kg LBM.d
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Women with short luteal phases
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Energy availability on plasma glucose, beta‐hydroxybutyrate, GH, and cortisol
Number of subjects: 29
Study: 10202582

Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 16
Study: 7540996

Group type: EXPERIMENTAL
Intervention: Escalating dosage of interferon alfa (starting at 3 million units, increasing to 5 million units at 8 weeks for nonresponders, and to 10 million units 8 weeks later for persistent nonresponders)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Constant dosage of interferon alfa (3 million units three times weekly for 24 weeks)
Number of subjects: 75
Study: 2212144

Group type: EXPERIMENTAL
Intervention: Topical formulation A of 2.5% hydrocortisone cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical formulation B of 2.5% hydrocortisone cream
Number of subjects: 0
Study: 648169

Group type: EXPERIMENTAL
Intervention: Griseofulvin every other day (5 mg/lb, max 1 gm/day)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Griseofulvin twice a week (5 mg/lb, max 1 gm/day)
Number of subjects: 247